It is estimated that the pharmaceutical packaging material market in Europe (including Eastern Europe) has annual sales of 3.246 billion U.S. dollars. The main packaging forms are containers and cartons, each of which accounts for 1/4 of total sales: followed by blister packs (including PVC strips and pouches), which account for about 22% of the rest by bottle closures, labels and other categories. The drug delivery system occupies. In terms of materials, paper and paperboard sales accounted for 37%, plastic sales accounted for 28%, metal sales accounted for 26%, and glass sales accounted for only 9%.
Between now and 2007, sales of packaging materials are expected to increase in parallel with sales of pharmaceuticals, and the negative effect of reducing the weight of packaging will be balanced by high-value packaging trends. In fact, package sales may grow faster than drug sales, although the rate will not be too great. This is because pharmaceutical companies are willing to purchase packages that are more expensive, safer, vandal-proof, child-resistant, convenient for the elderly, and can protect privacy. Therefore, compared with the $3.2 billion in 1998, the sales of pharmaceutical packaging reached $4 billion in 2002 and $5.1 billion in 2007. During the first half of this period, the growth rate of 5% to 6% will become 4% in the second half of the next 10 years. Glass products account for 9% of annual sales. Medicinal glass bottles are being challenged by plastics, but the excellent barrier properties and better sensory properties of glass can often make up for their fragile defects.
The development trend of packaging is having a complex impact on the glass industry because glass is seen as a better packaging material than plastic. For pharmaceutical manufacturers, image is becoming a higher priority. On the contrary, this trend is shifting containers to blister packs, which, though slow, will likely increase pace. In the United Kingdom, traditional pharmacists will ban the dispensing of tablets into bottles. As mentioned earlier, bottles used to repack pills are now often plastic.
Due to the impact of the package management regulations on glass sales, there will be a reduction in usage in the short term and a further slight decline in 2007. However, stable products will still be packaged in glass, not only because of their good quality, but also because there is no room for choice for some pharmaceutical packaging.
There is a trend in the market to resist the use of medicinal glass bottles. Even if the glass does not seem to be challenging (such as the packaging of cough syrup), some pharmaceutical companies are beginning to accept products for a shorter period of time and have obtained the benefits of plastic packaging. Glass tubes can be used to produce ampoules, vials, and syringes. In fact, only 5% of these products are made from non-glass materials. This has become the main market for the glass industry, and it accounts for the bulk of the quantity and value. With the development of many recombinant DNA products that can only be administered by the non-oral route, the production of ampoules and vials begins to increase. However, with the development of powder and liquid needleless injection systems, the use of common syringes will decline.
There will be no progress in the type and use of glass, but competitive drug delivery methods can reduce the number and types of injections, especially in Europe, including nasal sprays, inhalants, and oral forms (usually Enteric coated), transdermal patches and needleless injection delivery systems will affect the sales of glass packaging.
Between now and 2007, sales of packaging materials are expected to increase in parallel with sales of pharmaceuticals, and the negative effect of reducing the weight of packaging will be balanced by high-value packaging trends. In fact, package sales may grow faster than drug sales, although the rate will not be too great. This is because pharmaceutical companies are willing to purchase packages that are more expensive, safer, vandal-proof, child-resistant, convenient for the elderly, and can protect privacy. Therefore, compared with the $3.2 billion in 1998, the sales of pharmaceutical packaging reached $4 billion in 2002 and $5.1 billion in 2007. During the first half of this period, the growth rate of 5% to 6% will become 4% in the second half of the next 10 years. Glass products account for 9% of annual sales. Medicinal glass bottles are being challenged by plastics, but the excellent barrier properties and better sensory properties of glass can often make up for their fragile defects.
The development trend of packaging is having a complex impact on the glass industry because glass is seen as a better packaging material than plastic. For pharmaceutical manufacturers, image is becoming a higher priority. On the contrary, this trend is shifting containers to blister packs, which, though slow, will likely increase pace. In the United Kingdom, traditional pharmacists will ban the dispensing of tablets into bottles. As mentioned earlier, bottles used to repack pills are now often plastic.
Due to the impact of the package management regulations on glass sales, there will be a reduction in usage in the short term and a further slight decline in 2007. However, stable products will still be packaged in glass, not only because of their good quality, but also because there is no room for choice for some pharmaceutical packaging.
There is a trend in the market to resist the use of medicinal glass bottles. Even if the glass does not seem to be challenging (such as the packaging of cough syrup), some pharmaceutical companies are beginning to accept products for a shorter period of time and have obtained the benefits of plastic packaging. Glass tubes can be used to produce ampoules, vials, and syringes. In fact, only 5% of these products are made from non-glass materials. This has become the main market for the glass industry, and it accounts for the bulk of the quantity and value. With the development of many recombinant DNA products that can only be administered by the non-oral route, the production of ampoules and vials begins to increase. However, with the development of powder and liquid needleless injection systems, the use of common syringes will decline.
There will be no progress in the type and use of glass, but competitive drug delivery methods can reduce the number and types of injections, especially in Europe, including nasal sprays, inhalants, and oral forms (usually Enteric coated), transdermal patches and needleless injection delivery systems will affect the sales of glass packaging.
Squishy Painting Kit ,Paint Your Own Squishy,Color Your Own Squishy,Colour Your Own Squishy
Ningbo Shinegifts Import&Export Co., Ltd. , https://www.shinegifts.com